Back

SGLT2 inhibitors and endothelial function in dilated cardiomyopathy with HFrEF: a 12-month sex-based analysis

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - heart failure with HFrEF (4) Heart Failure with Reduced Ejection Fraction (HFrEF) Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Angelica Cersosimo

Teknon Medical Centre, Barcelona (Spain)

7 More presentations in this session

Presentation thumbnail
Prognostic impact of iron deficiency in patients hospitalised with acute decompensated heart failure with reduced ejection fraction and chronic kidney disease
Doctor V. Dimitrova (Sofia, BG)
Abstract Slides
Presentation thumbnail
Revascularisation strategy in ischemic heart failure: coronary artery bypass grafting versus percutaneous coronary intervention
Doctor A. Ben Salem (Tunis, TN)
Abstract Slides
Presentation thumbnail
Reverse cardiac remodeling and functional improvement with SGLT2 inhibitors in HFrEF: update from REWIN-HFrEF Study
Doctor L. Luzzi (Brescia, IT)
Abstract Slides
Presentation thumbnail
Additional prognostic effect of sacubitril-valsartan and SLGT2-Inhibitors on optimal medical therapy in patients with non-ischaemic dilated cardiomyopathy
Doctor C. Pio Loco detto Gava (Montebelluna, IT)
Abstract Slides
Presentation thumbnail
Association of body mass index with cardiopulmonary efficiency and ventricular remodeling in advanced heart failure
Doctor N. Andjelkovic (Belgrade, RS)
Abstract Slides

Access the full session

Session thumbnail
ePosters in chronic heart failure - heart failure with HFrEF (4)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources